Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Written informed consent has been obtained;~* ≥18 years of age;~* Suspected MRSA bacteremia determined by clinical judgment or 2 sets of positive blood cultures;~* Increased risk for an MRSA infection~EXCLUSION CRITERIA:~* Received \>48 hours of vancomycin therapy in the 7 days prior to enrollment;~* Received any systemic antibacterial agents potentially effective against MRSA in the 7 days prior to enrollment;~* Anticipated requirement of antibiotics potentially effective against MRSA;~* High likelihood of left-sided infective endocarditis (LIE);~* Known/suspected polymicrobial bacteremia or infection including Gram-negative infections;~* Known pneumonia, osteomyelitis, or meningitis;~* Intravascular foreign material unless material intended removed within 3 days;~* Prosthetic heart valve;~* Cardiac decompensation, valve damage, or both such that high likelihood of valve replacement surgery within first 3 days of study drug treatment;~* Moribund clinical condition such that death likely within first 3 days of study drug treatment;~* Shock or hypotension or oliguria unresponsive to fluids after 4 hours;~* Received investigational drug within 30 days of study entry~* Received statins or other therapy with associated with rhabdomyolysis within 2 days of study entry;~* History of significant allergy or intolerance to vancomycin or daptomycin~* Infecting pathogen with confirmed reduced susceptibility to vancomycin;~* Infecting pathogen with confirmed reduced susceptibility to daptomycin~* Creatinine clearance \<30 mL/min (Cockcroft-Gault equation actual body weight)~* Serum creatine phosphokinase (CPK) ≥500 U/L~* Alanine transaminase (ALT) or aspartate aminotransferase (AST) \>5 X ULN;~* Total bilirubin ≥3.0 mg/dL;~* Severe neutropenia or expected development severe neutropenia during study;~* Known or suspected HIV infection with a CD4+ T-cell count \<200/μL;~* Unlikely to comply with study procedures or return for evaluations;~* Body Mass Index (BMI) ≥40 kg/m2;~* Pregnant or nursing;~* Female of childbearing potential not willing to practice barrier methods of birth control.~CONTINUATION CRITERIA:~* Fulfills A or B or both: A) Confirmed complicated MRSA bacteremia B) Possible or definite RIE caused by MRSA according to modified Duke criteria;~* Infecting S. aureus strain susceptible to vancomycin;~* Infecting S. aureus strain susceptible to daptomycin;~* Appropriate treatment of any foci of infection within first 3 days of study;~* Removal of any intravascular foreign material not allowed per inclusion criteria within first 3 days of study;~* Removal of any percutaneous or implanted catheters not allowed per inclusion criteria within first 3 days of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- daptomycin 10 mg/kg (Type: EXPERIMENTAL): Daptomycin 10 mg/kg IV every 24 hours
- vancomycin high-dose (Type: EXPERIMENTAL): Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).